Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Sponsored
Interactive Tools
Learning Modules
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma - Episode 5
Transitioning From Locoregional to Systemic Therapy
June 29, 2020
Peter R. Galle, MD, PhD, Mainz University Medical Center
,
Minsig Choi, MD, Stony Brook University Hospital
,
Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine
,
Kate Kelley, MD, UCSF Health
EP. 1: HCC Etiologic Risk Factors and Global Prevalence
EP. 2: HCC Global Screening Programs for At-Risk Populations
EP. 3: The Evolving Role of Medical Oncologists and Hepatologists
EP. 4: HCC Diagnosis and Prognosis
Now Viewing
EP. 5: Transitioning From Locoregional to Systemic Therapy
EP. 6: HCC Treatment Algorithm: Asia and Europe
EP. 7: Frontline Decision Factors for Metastatic Disease
EP. 8: Phase 3 IMbrave150 Trial
EP. 9: Frontline Therapy: Promising I/O Combinations
EP. 10: Frontline I/O: Clinical Trial Overviews
EP. 11: R/R HCC: Second-Line Options
EP. 12: Second-Line Sequencing After IMbrave150 Regimen
EP. 13: Second-Line Therapy: Monoclonal Antibody
EP. 14: REACH and REACH2 Trial Overview
EP. 15: I/O Second-Line Treatment
EP. 16: Metastatic HCC Unmet Needs
EP. 17: Emerging Therapies for HCC Management
Related Content:
Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma
Emerging Therapies for HCC Management
Metastatic HCC Unmet Needs
I/O Second-Line Treatment
